MCM
ALPN

Moore Capital Management’s Alpine Immune Sciences Inc ALPN Stock Holding History

Moore Capital Management’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,744
Closed -$157K – 566
2023
Q3 		$157K Sell
13,744
-100
-0.7% -$1.23K ﹤0.01% 378
2023
Q2 		$142K Buy
+13,844
New +$125K ﹤0.01% 388

Other funds holding ALPN

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Moore Capital Management's ALPN Position: Q4 2023 in Review

Moore Capital Management sold out of Alpine Immune Sciences Inc (ALPN) in Q4 2023, closing a stake of 13,744 shares — an estimated $157K sold.

Moore Capital Management first reported a position in ALPN in Q2 2023 and held it in 2 quarters. The position peaked at $157K in Q3 2023. 133 funds tracked by Wall St. Rank hold ALPN as of Q4 2023.

  • Moore Capital Management reported no remaining Alpine Immune Sciences Inc position as of Q4 2023 after selling out during the quarter.
  • Moore Capital Management sold 13,744 Alpine Immune Sciences Inc shares in Q4 2023, an estimated $157K.
  • Moore Capital Management first reported a position in Alpine Immune Sciences Inc in Q2 2023 and held it in 2 quarters.
  • Moore Capital Management's Alpine Immune Sciences Inc position peaked at $157K in Q3 2023.
  • 133 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q4 2023.

Based on Moore Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.